Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Placebo-Controlled, Multiple-Ascending-Dose Investigation of the Oral Anti-Inflammatory Agent BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Placebo-Controlled, Multiple-Ascending-Dose Investigation of the Oral Anti-Inflammatory Agent BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADS 051 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions
  • Acronyms SCOUT
  • Sponsors Adiso Therapeutics; Bacainn Therapeutics

    • Most Recent Events

    • 22 Oct 2023 According to an Adiso Therapeutics media release, based on positive topline results from this study company has recently completed positive end-of-Phase 1 FDA interaction, and planning to advance ADS051 in a Phase 2 clinical study in early 2024.
    • 22 Oct 2023 According to an Adiso Therapeutics media release, results from this study were presented at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting being held October 20-25, in Vancouver, Canada.
    • 22 Oct 2023 Positive topline results from this trial presented in an Adiso Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top